Lilly's triple G overpowers Ozempic in diabetes trial
Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.
Newsletters and Deep Dive digital magazine
Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.
Switzerland's Ferring Pharma has reached an agreement to buy US fertility start-up Gameto for up to $1.38bn.
Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."
There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.
What constitutes a reliable supply chain is changing rapidly.
Editor's Picks
Newsletters and Deep Dive
digital magazine